Skip to main content
Bruce Trapnell, MD, Pulmonology, Cincinnati, OH, Cincinnati Children's Hospital Medical Center

BruceColstonTrapnellMD

Pulmonology Cincinnati, OH

Critical Care Medicine

Professor, Pediatrics, University of Cincinnati College of Medicine

Dr. Trapnell is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Trapnell's full profile

Already have an account?

Education & Training

  • Clinical Center at the National Institutes of Health
    Clinical Center at the National Institutes of HealthFellowship, Pulmonary Disease and Critical Care Medicine, 1988 - 1989
  • Clinical Center at the National Institutes of Health
    Clinical Center at the National Institutes of HealthFellowship, Pulmonary Disease and Critical Care Medicine, 1987 - 1988
  • Ohio State University Hospital
    Ohio State University HospitalResidency, Internal Medicine, 1984 - 1987
  • University of Maryland School of Medicine
    University of Maryland School of MedicineClass of 1984

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 1998 - 2025
  • LA State Medical License
    LA State Medical License 2021 - 2022
  • DC State Medical License
    DC State Medical License 1992 - 1998
  • MD State Medical License
    MD State Medical License 1987 - 1991
  • American Board of Internal Medicine Internal Medicine

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis  
    Bruce Trapnell, MD, New England Journal of Medicine

Press Mentions

  • Savara Announces First Patient Dosed in Pivotal Phase 3 Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Trial
    Savara Announces First Patient Dosed in Pivotal Phase 3 Autoimmune Pulmonary Alveolar Proteinosis (aPAP) TrialJune 30th, 2021
  • New England Journal of Medicine
    New England Journal of MedicineSeptember 8th, 2020
  • Savara Announces FDA Response from Type C Meeting on Molgradex for aPAP Development Program
    Savara Announces FDA Response from Type C Meeting on Molgradex for aPAP Development ProgramOctober 2nd, 2019
  • Join now to see all

Grant Support

  • Role Of GM-CSF In Myeloid Cell Function And Innate ImmunityNational Heart, Lung, And Blood Institute2011–2012
  • Macrophage-Based Human Gene Therapy For Hereditary PAPNational Heart, Lung, And Blood Institute2011–2012
  • Role Of Anti-Gm-Csf Antibodies In Myeloid Cell Function &Innate ImmunityNational Heart, Lung, And Blood Institute2010
  • Role Of Anti-Gm-Csf Antibodies In Myeloid Cell Function &Innate ImmunityNational Heart, Lung, And Blood Institute2007–2009
  • Quantitative Chest Computed Tomography In Alpha-1-Antitrypsin DeficiencyNational Center For Research Resources2008
  • Anticytokine Autoantibodies/Growth Factors In RARE Lung DiseasesNational Center For Research Resources2005–2008
  • RARE Lung Disease Clinical Research NetworkNational Center For Research Resources2003–2008
  • AAT Deficiency &Liver Diseases Caused By ProteinsNational Institute Of Diabetes And Digestive And Kidney Diseases2006
  • Fourth Annual International Pulmonary Alveolar Proteinosis Research ConferenceNational Heart, Lung, And Blood Institute2006
  • Regulation Of Alveolar Macrophage PhagocytosisNational Heart, Lung, And Blood Institute2003–2006
  • Pulmonary Alveolar Proteinosis Research ConferenceNational Heart, Lung, And Blood Institute2005
  • Conference--Pulmonary Alveolar Proteinosis ResearchNational Heart, Lung, And Blood Institute2004
  • GM-CSF &Alveolar Macrophage Antiviral Lung DefenseNational Heart, Lung, And Blood Institute2001–2004
  • Core--Viral VectorsNational Heart, Lung, And Blood Institute1997

Hospital Affiliations